News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Achaogen Announces All Objectives Met in Phase 2 Plazomicin Complicated Urinary Tract Infections Study and Start of First-in-Human Study with ACHN-975



5/15/2012 10:33:55 AM

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Achaogen, Inc. announced today that all objectives were met in the company's multi-national Phase 2 study of plazomicin compared to levofloxacin for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis in adults. Achaogen is developing plazomicin, a next-generation aminoglycoside that overcomes common bacterial resistance mechanisms, as an intravenous treatment for serious Gram-negative bacterial infections, including those caused by multi-drug resistant (MDR) Escherichia coli and Klebsiella pneumoniae. In addition, the Biomedical Advanced Research and Development Authority (BARDA) previously awarded Achaogen up to $64.5 million in funding to support the development of plazomicin as a potential medical countermeasure against the biothreat pathogens, Yersinia pestis and Francisella tularensis.

Read at BioSpace.com


comments powered by Disqus
Achaogen
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES